Clinical Trials
8
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2003
Completed
8
100.0%
No approval data available
- Verrica Pharmaceuticals' VP-315 demonstrated a potential abscopal effect in Phase 2 trials, with untreated basal cell carcinoma lesions showing a 67% reduction in size following treatment of separate target lesions. - The oncolytic peptide immunotherapy achieved complete histologic clearance in 21% of non-treated lesions, suggesting broader immune activation beyond the injection site. - Results indicate VP-315 could address the significant unmet need for patients with multiple BCC lesions, as approximately one-third of patients develop additional primary tumors over their lifetime. - The therapy reduced overall tumor size by an average of 86% in treated lesions, potentially improving patient outcomes by reducing the complexity of future surgical procedures.
- Verrica Pharmaceuticals raised approximately $50 million through a private placement financing to retire debt and extend operations into mid-2027. - The company will use $35 million to fully repay OrbiMed debt obligations, eliminating restrictive covenants and interest payments. - Financing enables advancement of VP-315 Phase 3 trials for basal cell carcinoma and global Phase 3 program for common warts starting before end of 2025. - YCANTH remains the only FDA-approved treatment for molluscum contagiosum, affecting approximately 6 million Americans primarily children.
- The European Medicines Agency's Committee for Medicinal Products for Human Use concluded that existing Phase 3 data from U.S. and Japan studies are sufficient to support YCANTH's approval in Europe for molluscum contagiosum treatment. - YCANTH is the first and only FDA-approved healthcare professional-administered treatment for molluscum contagiosum, affecting an estimated six million people in the United States primarily children. - Verrica plans to file the Marketing Authorization Application as early as Q4 2026, targeting the significant unmet medical need in the European molluscum market. - The regulatory feedback provides alignment on study design acceptability, clinical safety data requirements, and adequacy of nonclinical studies for the European filing.
- Verrica Pharmaceuticals will present new data on VP-315, its oncolytic peptide therapy for basal cell carcinoma, at the Society for Immunotherapy of Cancer 40th Annual Meeting in November 2025. - The presentation will focus on exploratory analysis of local immune activation in the tumor microenvironment 12 weeks post-treatment with VP-315 from a Phase 2 multicenter study. - VP-315 is a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy that induces immunogenic cell death and unleashes tumor antigens for T cell responses, offering a non-surgical treatment option. - The therapy has demonstrated positive tumor-specific immune cell responses in multi-indication Phase 1/2 oncology trials and is based on pioneering research in host defense peptides.
- Verrica Pharmaceuticals achieved a milestone with over 10,000 YCANTH® dispensed applicator units in Q1 2025, representing a 16.7% sequential increase from the previous quarter. - The company reports normalized distribution inventory levels, indicating that dispensed units will now more closely track actual demand and gross revenue. - Following a commercial restructuring, Verrica is positioned for sustainable revenue growth as it works to establish YCANTH® as the standard of care for molluscum contagiosum.
